Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Sjoquist KM, Friedlander ML, O'Connell RL, Voysey M, King MT, Stockler MR, Oza AM, Gillies K, Martyn JK, Butow PN. Sjoquist KM, et al. Oncologist. 2013;18(11):1221-8. doi: 10.1634/theoncologist.2013-0175. Epub 2013 Oct 9. Oncologist. 2013. PMID: 24107972 Free PMC article.
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML, Stockler M, O'Connell R, Voysey M, Oza A, Gillies K, Donovan H, Martyn J, Sjoquist K, Butow P, King MT; Symptom Benefit Study Group. Friedlander ML, et al. Int J Gynecol Cancer. 2014 Jun;24(5):857-64. doi: 10.1097/IGC.0000000000000147. Int J Gynecol Cancer. 2014. PMID: 24844219
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT, Stockler MR, Butow P, O'Connell R, Voysey M, Oza AM, Gillies K, Donovan HS, Mercieca-Bebber R, Martyn J, Sjoquist K, Friedlander ML. King MT, et al. Int J Gynecol Cancer. 2014 Jun;24(5):865-73. doi: 10.1097/IGC.0000000000000167. Int J Gynecol Cancer. 2014. PMID: 24844220
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI); Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG). Chantrill LA, et al. Clin Cancer Res. 2015 May 1;21(9):2029-37. doi: 10.1158/1078-0432.CCR-15-0426. Clin Cancer Res. 2015. PMID: 25896973 Clinical Trial.
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Pavlakis N, et al. Among authors: sjoquist km. J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325864 Free PMC article. Clinical Trial.
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Bonaventura A, et al. Among authors: sjoquist km. Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978. Int J Gynecol Cancer. 2017. PMID: 28498256 Clinical Trial.
52 results